ABCL
NASDAQ
CA
AbCellera Biologics Inc. - Common Shares
$3,52
▲ +$0,01
(+0,28%)
Vol. 3.5M
4
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$1.0B
ROE
-17,0%
Margine
-486,0%
D/E
0,00
Beta
0,78
52W
$2–$7
Consenso Wall Street
14 analisti · Apr 20263
Acquisto forte
9
Compra
2
Mantieni
0
Vendi
0
Vendita forte
85,7%
Rating Compra
Grafico dei Prezzi
Utili
Tasso di battuta: 50,0%
Prossimo report
Mag 06, 2026
Stima EPS: $-0,19
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,19 | — | — |
| Dic 2025 | $-0,18 | $-0,03 | +$0,15 |
| Set 2025 | $-0,17 | $-0,19 | $-0,02 |
| Giu 2025 | $-0,17 | $-0,12 | +$0,05 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $5.0M | $4.2M | $17.1M | $9.0M | $44.9M |
| Utile netto | — | -$34.2M | -$45.6M | -$34.7M | -$57.1M | -$8.9M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -15.9% | -15.9% | -15.9% | -15.9% | -17.0% | -17.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -203.3% | -503.9% | -503.9% | -503.9% | -486.0% | -486.0% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 11.07 | 11.07 | 11.07 | 11.07 | 10.10 | 10.10 |
Rapporti chiave
ROA (TTM)
-12,6%
P/S (TTM)
28,98
P/B
0,8
EPS (TTM)
$-0,58
CF/Share
$-0,34
Crescita ricavi 3A
-57,5%
52W High
$6,52
52W Low
$1,89
$1,89
Intervallo 52 settimane
$6,52
Salute finanziaria
Flusso di cassa libero
-$44.6M
Debito netto
$14.7M
Liquidità
$128.5M
Debito totale
$143.2M
Aggiornato al Dic 31, 2025
Як ABCL виглядає на тлі конкурентів у Life Sciences Tools & Services?
Група порівняння: Small-cap Life Sciences Tools & Services ($300M+) · 25 компаній
Оцінка ABCL vs аналоги Life Sciences Tools & Services
P/E
—
▼
0%
sotto
peer
(32,5)
vs Peer
vs Settore
Valore equo
P/S
29,0
▲
659%
sopra
peer
(3,8)
vs Peer
vs Settore
Sopravvalutato
P/B
0,8
▼
78%
sotto
peer
(3,7)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,5%)
vs Peer
vs Settore
Rendimento basso
Прибутковість ABCL vs аналоги Life Sciences Tools & Services
ROE
-17,0%
▼
418%
sotto
peer
(-3,3%)
vs Peer
vs Settore
Debole
Net margin
-486,0%
▼
5076%
sotto
peer
(-9,4%)
vs Peer
vs Settore
Debole
Валова маржа
—
▼
0%
sotto
peer
(48,0%)
vs Peer
vs Settore
Top livello
ROA
-12,6%
▼
383%
sotto
peer
(-2,6%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя ABCL vs аналоги Life Sciences Tools & Services
D/E ratio
0,0
▼
100%
sotto
peer
(36,5)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
10,1
▲
199%
sopra
peer
(3,4)
vs Peer
vs Settore
Liquidità forte
Beta
0,8
▼
45%
sotto
peer
(1,4)
vs Peer
vs Settore
Più volatile
Радар фундаменталів ABCL
ABCL
Mediana peer
Industria
ABCL прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ABCL vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
THERMOPYLAE HOLDINGS, LTD.
Beneficial Owner of more than… · Feb 27
38000 shs
BOOTH ANDREW
Chief Financial Officer · Feb 27
42600 shs
THERMOPYLAE HOLDINGS, LTD.
Beneficial Owner of more than… · Feb 26
177457 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 19,62%Baker Bros. Advisors, LP
9,08%
$90.0M
Capital World Investors
4,41%
$43.7M
UBS AM, a distinct business…
2,60%
$25.8M
Two Sigma Investments, LP
1,92%
$19.0M
Two Sigma Advisers, LP
1,61%
$16.0M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora